{"groups":[{"description":"Oral rucaparib (monotherapy).\n\nRucaparib: Rucaparib will be administered daily.","id":"FG000","title":"Rucaparib"},{"description":"Oral abiraterone acetate (monotherapy, given in combination with prednisone). Oral enzalutamide (monotherapy). Intravenous docetaxel (monotherapy, given in combination with prednisone or prednisolone).\n\nAbiraterone acetate or Enzalutamide or Docetaxel: Abiraterone acetate and enzalutamide will be administered daily.\n\nDocetaxel will be administered every 3 weeks.","id":"FG001","title":"Abiraterone Acetate or Enzalutamide or Docetaxel"},{"description":"Oral rucaparib (monotherapy).\n\nRucaparib: Rucaparib will be administered daily. Participants from the Abiraterone Acetate/Enzalutamide/Docetaxel arm who completed the Treatment Phase and radiographically progressed by independent radiology review (IRR) may receive rucaparib treatment during the Cross-Over Phase.\n\nAfter analysis of the primary endpoint, investigator-assessed radiographic disease progression will be used for cross-over eligibility evaluation.","id":"FG002","title":"Rucaparib (Cross-Over Phase)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"0"}],"type":"Never initiated study drug"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"270"},{"groupId":"FG001","numSubjects":"135"},{"groupId":"FG002","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"270"},{"groupId":"FG001","numSubjects":"130"},{"groupId":"FG002","numSubjects":"0"}],"type":"Received at Least 1 Dose of Study Drug"},{"achievements":[{"groupId":"FG000","numSubjects":"270"},{"groupId":"FG001","numSubjects":"130"},{"groupId":"FG002","numSubjects":"0"}],"type":"Safety Population"},{"achievements":[{"groupId":"FG000","numSubjects":"270"},{"groupId":"FG001","numSubjects":"130"},{"groupId":"FG002","numSubjects":"0"}],"comment":"Treatment period completion was defined as discontinuation when criteria for treatment discontinuation were met.","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Treatment Phase"},{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"70"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"70"}],"type":"Received at Least 1 Dose of Study Drug"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"70"}],"type":"Safety Population"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"70"}],"comment":"Crossover period completion was defined as discontinuation when criteria for treatment discontinuation were met, or study closure.","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Cross-Over Phase"}]}